EMA to draft policy on public access to clinical data

05/5/2013 | PharmaTimes (U.K.)

The European Medicines Agency has announced a timetable for its policy on publicly releasing medical data from clinical trials. The EMA plans to release the draft policy in June, receive public comments through September and publish its final policy at the end of November, with implementation scheduled for January 2014. The final policy will take into account rulings on court cases challenging data transparency mandates, including a recent European Union interim court injunction in favor of drugmakers AbbVie and InterMune. The EMA said its final policy will balance public health interests with the need for patient confidentiality and protection of intellectual property rights.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC